Skip to main content
. Author manuscript; available in PMC: 2022 Nov 28.
Published in final edited form as: Clin Genitourin Cancer. 2022 Feb 1;20(3):260–269. doi: 10.1016/j.clgc.2022.01.017

Figure 2.

Figure 2.

Proton pump inhibitor (PPI) use by indication (A), ordering provider (B), and duration (C) in 104 (59.1%) patients who had PPI exposure from 3 months prior to ICI initiation until ICI colitis, death, or last ICI infusion, whichever occurred first. GERD: gastroesophageal reflux disease, PUD: peptic ulcer disease, GIB: gastrointestinal bleeding, ICI: immune checkpoint inhibitor, ICU: intensive care unit. *Other indications include diarrhea, nausea, abdominal pain, and GI prophylaxis on medical/surgical wards.